Health
Moderna Announces Publication in The New England Journal of Medicine of Interim Results From Older Adult Age Cohorts in Phase 1 Study of its mRNA Vaccine Against COVID-19 (mRNA-1273) – Business Wire
Moderna announces publication of interim results from older adult age cohorts in Phase 1 study of its mRNA vaccine in NEJM.
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the publication of the second interim analysis of the open-label Phase 1 study of mRNA-1273, its vaccine candidate against COVID-19, inThe New England Journal of Medicine. This interim analysis evaluated a two-dose vaccination schedule of mRNA-1273 given 28 days apart…
-
Business24 hours agoWhy Amotiv, Breville, Life360, and Woodside shares are tumbling today
-
Noosa News22 hours agoDevastating update in search for missing Queensland mother Tayla Spies as police find human remains near her ute
-
Business20 hours agoOwn the world with these 3 global ASX ETFs
-
General22 hours agoHousing affordability. The crisis the major parties are too scared to fix